Evidence map›Paper›PMID 29126386›Full record

SynthesisBMC cancer2017

Venous thromboembolism and mortality in breast cancer: cohort study with systematic review and meta-analysis.

Umair T Khan, Alex J Walker, Sadaf Baig, Tim R Card, Cliona C Kirwan, Matthew J Grainge

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Venous thromboembolism incidence in cancer patients with germline BRCA mutations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Observational
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Umair T KhanDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK.
Alex J WalkerDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK.
Sadaf BaigDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK.
Tim R CardDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK.
Cliona C KirwanInstitute of Cancer, University of Manchester, South Manchester University Hospitals NHS Trust, Wythenshawe Hospital, Southmoor Road, Manchester, M23 9PL, UK.
Matthew J GraingeDivision of Epidemiology and Public Health, School of Medicine, University of Nottingham, Medical School, Nottingham, NG7 2UH, UK. matthew.grainge@nottingham.ac.uk.
University of Nottingham · GBUniversity of Liverpool · GBUniversity of Manchester · GB

Funding

Cancer Research UK 12079Cancer Research UK C17683/A12079Department of Health NIHR-CS-011-014
6 · The paper itself

Abstract

backgroundBreast cancer patients are at an increased risk of venous thromboembolism (VTE). However, current evidence as to whether VTE increases the risk of mortality in breast cancer patients is conflicting. We present data from a large cohort of patients from the UK and pool these with previous data from a systematic review.

methodsUsing the Clinical Practice Research Datalink (CPRD) dataset, we identified a cohort of 13,202 breast cancer patients, of whom 611 were diagnosed with VTE between 1997 and 2006 and 12,591 did not develop VTE. Hazard ratios (HR) were used to compare mortality between the two groups. These were then pooled with existing data on this topic identified via a search of the MEDLINE and EMBASE databases (until January 2015) using a random-effects meta-analysis.

resultsWithin the CPRD, VTE was associated with increased mortality when treated as a time-varying covariate (HR = 2.42; 95% CI, 2.13-2.75), however, when patients were permanently classed as having VTE based on presence of a VTE event within 6 months of cancer diagnosis, no increased risk was observed (HR = 1.22; 0.93-1.60). The pooled HR from seven studies using the second approach was 1.69 (1.12-2.55), with no effect seen when restricted to studies which adjusted for key covariates.

conclusionA large HR for VTE in the time-varying covariate analysis reflects the known short-term mortality following a VTE. When breast cancer patients are fortunate to survive the initial VTE, the influence on longer-term mortality is less certain.

Indexed as

AnticoagulantsBreast NeoplasmsCohort StudiesFemaleHumansMEDLINEProportional Hazards ModelsRisk FactorsVenous ThromboembolismAnticoagulantsBreast cancerCohort studyDeep vein thrombosisMeta-analysisMortalityPrognosisPulmonary embolismSystematic reviewVenous thromboembolism

Identifiers

PMID29126386
PMCPMC5681811
OpenAlexW2767276147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.